Calliditas Therapeutics Ab (CLTEF) Stock Overview
Explore Calliditas Therapeutics Ab’s financial performance, market position, analyst ratings, and future outlook.
Calliditas Therapeutics Ab (CLTEF)
Key Financials
Key Financials
Market Cap
14.7M
P/E Ratio
-4.37
EPS (TTM)
N/A
ROE
-0.65%
CLTEF Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of Calliditas Therapeutics Ab (CLTEF) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of C+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
The current technical analysis reveals key indicators including an RSI of 40.67, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $0.05.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -4.37 and a market capitalization of 14.7M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.